Long QT Syndrome Presentations

Abstract presented at the 2024 Heart Rhythm Society Conference in Boston, MA on May 17th, 2024. These preclinical data support the continued development of SGK1-I as a novel therapeutic for DI-QTP and LQTS2.

“Attenuation of Drug-Induced QT-Prolongation in Guinea Pig Isolated Heart and Anesthetized Dog Models of Drug-Induced QT Prolongation by Serum/Glucocorticoid Regulated Kinase 1 (SGK-1) Inhibitor”

Abstract presented at the 2024 American College of Cardiology Conference in Atlanta, Georgia on April 7th, 2024. The Wave I Proof of Concept clinical study evaluated LQT-1213 for the reduction of QTcF in individuals with dofetilide-induced long QT Syndrome.

Abstracts presented at the 2022 American Heart Association Scientific Session from research performed in collaboration with the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory directed by Dr. Michael Ackerman, MD, Ph.D.

“SGK1 Inhibition Attenuated the Action Potential Duration in Patient- and Genotype-Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome”

“SGK1 Inhibition and Attenuation of the Action Potential Duration in Re-Engineered Heart Cell Models of Drug-Induced QT Prolongation”

“SGK1 Inhibitor LQT-1213 (Islasertib) Promotes Significant Reduction in QTc Prolongation in a Dofetilide-Induced Human Model of Long QT Syndrome (LQTS) in the WAVE I Clinical Study”

Scientific Data Presentations

Long QT Syndrome Presentations

Thryv Therapeutics Inc.